Close Window

Digital Look Email A Friend

Losses widen as Evgen Pharma develops SFX-01

Published by Josh White on 15th June 2020

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported a slight widening of its post-tax loss in its final results on Monday, to 2.7m, from 2.6m in the prior year.


Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.